PMN Stock — ProMIS Neurosciences Inc.

Up next

Latest filing: 10-Q

filed Aug 13, 2026

Q2 2026 earnings call transcript

call held Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

—

Trailing 12 months

Net income (TTM)

−$42.23M

Trailing 12 months

Revenue growth YoY

—

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+555.8%

Year over year · more shares

Price change (1Y)

—

Trailing year

Short interest

2.7%

Latest settlement · 4.8 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026

Q2 FY26

TL;DR. ProMIS reported blinded six-month interim data from the PRECISE-AD Phase 1b trial of PMN310 in early Alzheimer's patients showing zero ARIA-E cases and directionally favorable biomarker movements (plasma pTau217 down ~15%, CSF MTBR-tau243 down ~13.3%), with unblinded 12-month topline results including cognitive outcomes expected in Q1 2027; the company ended Q2 with $53.4 million in cash, expected to fund operations through 2027.

Bullish

+ Blinded interim PRECISE-AD analysis showed zero ARIA-E cases across all 136 safety-evaluable participants, including APOE4 homozygotes.
+ Blinded pooled biomarker data showed directionally favorable declines in plasma pTau217 (~15%) and CSF MTBR-tau243 (~13.3%), consistent with the trial's 75% active-drug allocation.
+ Cash position strengthened to $53.4 million with runway through 2027, beyond the anticipated Q1 2027 PRECISE-AD topline readout.
+ Pipeline advancing with PMN267 (TDP-43/ALS) progressing through IND-enabling studies and PMN442 (alpha-synuclein) advancing toward IND-enabling studies.
+ Company presented first human evidence of Aβ oligomer target engagement and removal by PMN310 at AAIC 2026.

Bearish

− Net loss widened to $11.7 million in Q2 2026 from $10.1 million in Q2 2025, with R&D expense rising to $9.5 million.
− Accumulated deficit grew to $150.4 million as of June 30, 2026, reflecting continued operating losses.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Weak Sentiment Very Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −27%

below

Price vs 50-day avg −30%

below

RSI (14) 28

oversold

MACD trend Negative

52-week position 14%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −26%

trailing

6-month return −22%

trailing

YTD return +37%

this year

Relative strength −34%

vs S&P · 6-mo

Sentiment

smart money

Very Bullish

Trend (MA cross) No cross

50d $13 › 200d $13 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +5 funds added

Insider flow Accumulating

Net +$30.3K over 90 days · 0% sells

Short interest Falling

2.68% of float · ▼ -9.0% MoM · 4.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

27 holders — near 3-yr high, broad support

Squeeze score 49

elevated · 0–100

Fundamentals

Weak

EPS growth −960%

Y/Y

Free cash flow $-28.1M

Balance sheet $12.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 97%

annualized · 1-yr

Max drawdown −63%

past year

ATR 11.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−27% Bearish

Price vs 50-day avg

−30% Bearish

RSI (14)

28 Neutral

MACD trend

Negative Bearish

52-week position

14% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) No cross

50d $13 › 200d $13 — 50d above 200d

Institutional flow Accumulating

+8% holders QoQ · +5 funds added

Insider flow Accumulating

Net +$30.3K over 90 days · 0% sells

Short interest Falling

2.68% of float · ▼ -9.0% MoM · 4.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

27 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $7 Now $9 · 14% Range high $25

vs 200-day avg -27% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
cash and short-term investments	$53.4M	As of June 30, 2026	—
Expenditures for PMN310	$7.8M	the three months ended June 30, 2026 filing	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
PMN ProMIS Neurosciences Inc. this stock	$101.07M	+37.2%	—	—	2.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

27

% held: 71.4%
Net QoQ: +259.2K sh
Top holder: Jupiter Topco LLC

Held Float

View

Held by Funds

Fund positions

2

View

Short & Settlement

Short Interest Falling

Shares short

240.0K

Days to cover: 4.8d
Change: -23.7K sh

View

Short Volume

Short vol %

36%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

265

Value: $3.6K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

41.4%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$30.3K

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Net income (FY)

$-39.7M

EPS diluted: $-22.61

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 10, 2026
This year: 11

View

Exempt Offerings

Offering

$10.1M

Filed: Oct 21, 2022

View

Earnings & Events

Webcasts

Last webcast

Sep 10, 2026

View

Investor Relations

Upcoming events

3

View

	5D	20D	120D	MTD	YTD
PMN	-12.0%	-25.6%	-22.2%	-13.6%	+37.2%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-13.2%	-26.2%	-33.8%	-15.2%	+23.6%

PMN · ProMIS Neurosciences Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance